Bengaluru, Karnataka, India, October 2024 – Pravin Kumar Arora has joined Biocon as the Cluster Head – API Operations. In his new role, Pravin will oversee all API manufacturing operations for the Bangalore cluster, ensuring adherence to budgetary, quality, and EHS standards. He will also be responsible for the P&L of the manufacturing sites and provide strategic leadership to drive operational efficiency.
Career Journey: Prior to joining Biocon, Pravin served as the Associate Vice President – Head of API Cluster Operations at Sun Pharma for nearly two years. In this role, he managed operations for three USFDA-approved API manufacturing sites, including hormones, steroids, and cephalosporins, ensuring compliance with regulatory and budgetary requirements while optimizing operational processes.
Before Sun Pharma, Pravin was the Director at Vittesh Pharma, where he led the entire business operation. Vittesh Pharma specialized in contract manufacturing and supply of chemicals, KSM, intermediates, and APIs. Pravin’s entrepreneurial venture helped establish strong partnerships in the pharmaceutical industry.
Pravin also held the position of Senior Vice President & Head of Corporate Quality & Compliance at Mankind Pharma. During his nearly five-year tenure, he led global quality initiatives, ensuring compliance and overseeing quality processes across the company, including their US subsidiary Lifestar Pharma.
At Apotex Pharmachem Inc., Pravin served as the Head of Quality & Compliance, where he successfully implemented global quality strategies and ensured operational excellence in compliance functions.
Pravin’s early career began at Lupin Limited, where he worked for over 13 years in various leadership roles, including Deputy General Manager – Quality Assurance and Senior Manager – Production. During this time, he gained vast experience in managing production and quality assurance at USFDA and WHO-approved manufacturing facilities.
Biocon Limited, India’s largest biopharmaceutical company, is a global leader in innovation-led pharmaceuticals. With a portfolio spanning small molecules, biologics, and biosimilars, Biocon serves over 120 countries and focuses on providing affordable healthcare solutions for chronic diseases like diabetes, cancer, and autoimmune disorders. Biocon is ranked among the top 3 biosimilar players globally and continues to lead the way in the development of novel biologics and biosimilars to meet global healthcare needs.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
